蒋忠远

Co-Chair of the United Nations Sustainable Development Goals Digital Health Global Action Foundation, UNSDG UNOP Digital Health Global Initiatives, Outstanding Advisor of the Center for Sustainable Development of Biodiversity at Royal Thai University of Technology, and Vice President of the Professional Committee of Quality Appraisal of
Chinese Medicine

Chinese Center for Disease Control and Prevention (CDC)
(中国疾病预防控制中心)

联合国可持续发展目标数字健康全球行动基金会联席主席 UNSDG UNOP Digital Health Global Initiatives
、泰国皇家理工大学生物多样性可持续发展中心杰出顾问
、世界中联中药质量鉴定专业委员会副会长 蒋忠远教授

Chairman

Chinese Foundation for Hepatitis
Prevention & Control

中国疾病预防控制中心

冯奕斌

Professor , Director

Thre University of Hong Kong – School of Chinese Medicine, Li Ka Shing
Faculty of Medicine

Dean Of The NUS Faculty of Food Science &
Technology & Chairman of the Standards Committee of The Singapore Government

National Unviersity of Singapore

Managing Director

Decheng Capital

MIT

Nobel Prize Laureate

Executive Director

華風茂

Chairman

BioMeta

2015 Nobel Prize Laureate – per Maki George hara will assist to
invite him to join WATW

Stanford University

Nobel Prize Laureate

University of California, Berkeley –
Dept of Molecular & Cell Biology

Nobel Prize Laureate

Xuanwu Hospital of Capital Medical
University

Professor of Orthopaedic Surgery & , By Courtesy, Of Materials Science & Enginnering & of
Bioenginnering

Standford

Acting CEO, Co-Founder

Potentiam

M.U.S.T. Prof PAUL TAM 谭广亨教授

Director

The Stanford Robotic Center

顏寧

Shenzhen Medical Academy of
Research and Translation

Founding Partner, Managing Partner

MUNG Legal

Founder & Managing Director

Decheng Capital

Directof of the Natural Medicine & Food Institue of
the UCL Faculty of Pharmacy

UCL 药学院天然药食院主任兼的 PROF MICHAEL HEINRICH
教授

Head of the Department of Natural Medicine and
Food At University Nagoya

UNIVERSITY NAGOYA 天然药食系主任PROF MAKINO
牧业教授

Found & Chief Scientific Officer

Shanghai ImmuXell Biotech Ltd.

Using cell theraphy successfully treated pancreatic cancer;
affiliated with Fudan University

President

Japanese Society of Anti-
Aging Medicine

Managing Director

Hong Kong University Clinical Trials
Centre

杉山治夫

Assistant Professor – Department of Cancer
Immunology

Osaka University

Deputy Chief Executive Officer (Strategic
Partnerships) & Sr. Consultant

National Cancer Centre Singapore

Maki

江宜蓁

Managing Director

Hong Kong Institute of Biotechnology

Prof Yu asked Gina Jiang to prepare talk on : Cell Theraphy
From Bench To Bed Side

原丈人

Group Chairman & CEO

DEFTA Partners

高福

Director – Chinese Center for Disease Control &
Prevention

University of Chinese Academy of
Sciences

张戈

Director – Chinese Medicine – Technology
Development Division / Institute of Precision Medicine & Innovative Drug Discovery

Hong Kong Baptist University

Faculty
Co-founder & CEO

Stanford University Tiki Health

Maki (Prof Han Chong Toh) – along with Prof Han Chong Toh co- founders of neoTILa and AI-Healthtech & cell theraphy company; has built his Digi health enterprise in Thailand . Big foucs on AI in healthcare, big data, informatics. Gave talk on data & bioinformatics at JP Morgan Healthcare Conference in
Jan 2025 .

Director – Dr. Erwin Neher’s Biophysics and
Innovative Medicines Laboratory

Macau University of Science and
Technology

Nobel Prize Laureate

Managing Director

CR-CP Life Science Fund

Assoc professor Pharmacology

National University of Singapore

Maki (Prof Han Chong Toh) – expert on stroke, ageing, dementia
& longevity

Managing Director

HK Longevity Medical Center

Founder & CEO

Ryoden Medical Holdings

Chairmand of Sicentific Board, Co-Founder Head
of the Ctr for the Genetics of Host Defence, UTSW

Potentiam; Univeristy of Teax
Southerwestern Medical Center

2011 Nobel Price in Physiology or Medicine

马忠民

Chairman / CEO

Revivallon BioPharma

Prof Yu adv he is asking him to joing WATW (WeChat)

Zhao

Chief Clinical Medical Expert at the Cell and Gene Therapy Research Center of Southern University of Science and Technology in Shenzhen of China.

Graduated from the Medical Department of Nanjing Medical University in 1982 in Nanjing, China.

From December 1982 to May 2004, worked in the Department of General Surgery at Beijing Friendship Hospital affiliated Capital Medical University in Beijing. Served as a resident physician, attending physician, and associate chief physician in the Department of General Surgery, engaged in clinical, teaching, and research work.

From August 1990 to March 1995, went to the Oncology Surgery Laboratory at Johns Hopkins University School of Medicine in USA to conduct postdoctoral research. The personal research results have been published in top international medical journals such as Circulation Journal, Journal of Clinical Investigation , Shock Journal, Surgery Journal and etc.

In May 2004, transferred to Beijing Haidian Hospital to establish the first Cancer Gene Therapy Center in China served as the center director and chief physician.

In April 2007, a comprehensive treatment center combining gene therapy, hyperthermia, and minimally invasive techniques was established at Beijing Yanhua Hospital in Beijing as the center director, chief medical expert.

From September 2015 to April 2023, served as the CEO of Beijing Ludaopei Hematology Hospital.

From March 2024 to present, Chief Clinical Medical Expert at the Cell and Gene Therapy Research Center of Southern University of Science and Technology in Shenzhen of China.

Since 2004, organized and build the medical team of the Cancer Gene Therapy Center at Beijing Haidian Hospital and Beijing Yanhua Hospital to actively explore and innovate the application of modern biological gene immune technology (P53 gene drugs, DC-CIK, NK, Car-T and other immune therapy technologies), minimally invasive surgery and non-invasive technology, traditional Chinese medicine technology, traditional surgery , radiotherapy and chemotherapy technology. Carried out multidisciplinary team (MDT) collaboration in clinical treatment, developed precise personalized technical plans to treat various types of advanced cancer patients, and formed a unique treatment concept and practice system.

Since 2004, the team has not only treated a large number of tumor patients from all over China, but also attracted nearly 1000 cancer patients from nearly 40 countries and regions, including the United States, Canada, Mexico, Panama, Germany, UK, Denmark, Sweden, Norway, Russia,  Netherlands, Spain, Romania, Greece, Turkey, Singapore, Malaysia, India, Pakistan, Phlippines, Thailand, Vietnam, Hong Kong and etc. It has become a Chinese hospital department with the largest number of international cancer patients since the founding of New China.

Our achievement has received widespread attention from the international oncology community and media. Since May 2005, when the Italian newspaper “Liberty” first published a report on cancer gene therapy centers, there have been over 20 international media outlets, such as the top global media outlets “Associated Press”, “Business Week”, “Washington Post”, “CBS”, “Red Herring”. The world’s mainstream media, such as German Economic Weekly, Canadian National Television CTV, British Television 4, German Television 2, Swedish National Television, Danish National Television, Norwegian Television, Turkey National Television, and Korean National Television, have all made extensive positive reports on the tumor gene therapy center of Beijing Haidian Hospital and Beijing Yanhua Hospital from different perspectives, which has won the honor for Chinese hospitals in the world.

Dr. Li Dinggang holds positions in some domestic and international professional schools/associations:

1. Member of Johns Hopkins Internal and Surgucal Society
2. Honorary President of the Macao Anti Cancer Charity Association in China
3. Executive Vice Chairman of the International Medical Tourism Branch of the China Healthcare International Exchange Promotion Association
4. Executive Director of the International Cryosurgery Association
5. Director of the Chinese Society of Cryotherapy
6. Director of China Pharmaceutical Biotechnology Association
7. Member of the Gene Therapy Branch of the China Medical Biotechnology Association
8. Executive Committee Member of Hospital Management Branch of China Association of Non Public Medical Institutions
9. Secretary General of the Cancer Prevention and Treatment Professional Committee of the Chinese National Health Association
10. Member of the General Surgery Society of the Beijing Branch of the Chinese Medical Association
11. Specially appointed expert of China Life Science Research and Development Foundation
12. Specially appointed experts of Cancer Prevention and Control Expert Guidance Committee of Hainan Province, China , etc

Xu Kecheng, a male of Han ethnicity, was born in August 1940 in Nantong, Jiangsu Province. He
currently serves as the President of Fuda Cancer Hospital in Guangzhou, Guangdong Province.
He is also a visiting professor at Nantong University and Shenzhen University. Dr. Xu is a
renowned expert in gastroenterology and oncology in China and has been battling liver cancer for
many years.Previously, Xu Kecheng held the position of Vice Chairman of the Gastroenterology
Society of the Guangdong Medical Association. Currently, he holds various positions including
Chairman of the International Clinical Hydrogen Medical Association, Chief President of Fuda
Cancer Hospital affiliated with Jinan University, Vice Chairman of the Gastroenterology
Professional Committee of the Chinese Association of Integrative Medicine, and Vice President
of the Gastroenterology Professional Committee of the China Health Promotion Foundation.Over
the past few decades, Dr. Xu has treated over 10,000 overseas patients and tens of thousands of
cancer patients and more of there with good results.

Liu Baochi, Professor, Chief Physician, Doctor of Medicine, and Doctoral Supervisor.

• Standing Committee Member of the Health Emergency Professional Committee of the Chinese Research Hospital Association, and Head of the Infection and Special Infection Group

• Standing Committee Member of the National Health Industry Enterprise Management Association, and President of the Cell Therapy Industry and Clinical Research Branch

He graduated from Henan Medical College in 1983.He served as the Director of the Expert Committee for Emergency Medical Rescue of Sudden Public Health Events in Henan Province.In 1997, he joined the Chinese Medical Team to Zambia and served as the Chief Medical Officer of the China-Zambia Friendship Hospital in 2000.In 2008, he was recruited to the Shanghai Public Health Clinical Center as the Director of Surgery. He has led the surgical team to perform surgical treatments for over 2,000 patients with HIV infections and surgical diseases and proposed a surgical risk score for HIV-infected patients.He has achieved good therapeutic effects in treating HIV-infected patients with decompensated liver cirrhosis using autologous bone marrow cell therapy.He pioneered ultrasound-guided precise intrahepatic portal vein infusion of autologous bone marrow nucleated cells for the treatment of liver cirrhosis and precise pancreatic infusion of bone marrow nucleated cells for the treatment of diabetes.both of which have shown good therapeutic outcomes. He has also applied autologous bone marrow nucleated cell therapy to treat conditions such as premature ovarian failure, male sexual dysfunction, knee osteoarthritis, and avascular necrosis of the femoral head, achieving satisfactory results.He has preserved autologous bone marrow cells for cancer patients before chemotherapy and reinfused the preserved bone marrow cells after chemotherapy to promote bone marrow reconstruction.He has edited 10 academic monographs, obtained 13 national patents, and published more than 160 papers.

Dr. Minghui Zhang is a pioneering researcher and practitioner in the field of immune cell therapy
in China.In 2004,he published a landmark cover article in Nature Immunology,elucidating how
the immune microenvironment can reverse dendritic cell function to maintain immune system
homeostasis. In 2002,he was the first to discover and systematically investigate the bidirectional
anti-tumor effects of the CD8+NKT(vNKT) subpopulation. Since 2010,he has spearheaded the
clinical research and application of vNKT cells,which have demonstrated remarkable efficacy in
treating mid-and late-stage solid tumors. Specifically, the five-year tumor-free rate(clinical cure
rate)for patients with stage III solid tumors following vNKT intervention exceeds 80%. For stage IV
colorectal cancer patients with postoperative liver or lung metastasis,a combination of minimally
invasive local tumor reduction and vNKT intervention has achieved a five-year tumor-free rate of
over 40%. Dr. Zhang has also developed a non-chemical therapeutic approach for chronic diseases, primarily
based on mesenchymal stem cells(MSCs) and intestinal microbiota management. This innovative
method has shown rapid and significant efficacy in treating type 2 diabetes, Hashimoto’s
thyroiditis, inflammatory bowel disease, Alzheimer’s disease, and stroke sequelae, often leading
to functional reversal or functional cure. Building on his extensive research and clinical experience, Dr.Zhang established the Lehe New
Medical Chronic Disease Rehabilitation Centerin China.This center offers a comprehensive suite
of services, including research, diagnosis, treatment, rehabilitation and health management, dedicated to improving the lives of patients with chronic diseases

Professor WENLIN HUANG, a senior professor at the Sun Yat-sen University Cancer
Center and Chief Scientist at Guangzhou Doublle Bioproduct Co., Ltd., enjoys the
State Council Special Government Allowance, is a selected talent under China’s Key
Talent Program, and has received the 7th National Invention Patent Gold Award. He
was also elected as a member of the European Academy of Sciences (2024) and is
among the top 100,000 scientists globally. Professor Huang is also the director of the Guangdong Provincial New Tumor Vaccine
Engineering Laboratory and the Guangdong Provincial Key Laboratory for the
Development of Targeted Tumor Therapeutic Drugs. He focuses on gene therapy drug
development, translational research, and tumor immunotherapy projects. From 1988
to 2001, he conducted research and academic work at prestigious institutions in the
United States, including the Higher Institute of Virus Research, the University of
Pennsylvania School of Medicine, and Princeton University. After returning to China in 2001, he joined the Sun Yat-sen University Cancer Center, where he served as the director of the Biological Therapy Center. He has led
numerous projects, including major new drug creation initiatives from the 11th to 13th
Five-Year Plans, 973 projects, and National Natural Science Foundation projects. As
the first author or corresponding author, he has published over 180 SCI papers in top
journals such as Nature Medicine, Nature Communications, PNAS, Gastroenterology, and JCI (H-index: 58). He holds 50 patents for inventions in the U.S., international
PCT, and China. He is the chief editor of national graduate textbooks such as
Molecular Virology (1st/2nd/3rd editions) and academic monographs like Signal
Transduction, Molecular Targeted Therapy of Cancer, Melanoma, and Principles of
Cancer Personalized Medicine. He also contributed to the national 8-year medical
curriculum textbook Oncology and Cancer Biotherapy. He has received numerous
awards, including the China National Science and Technology Progress Award
(Second Class, 2016), the Ministry of Education Natural Science First-Class Award
(2011), and the Guangdong Provincial Science and Technology Progress Award (First
Class, 2010, 2015). In the field of innovative drug translation, Professor Huang has made significant
achievements. With a broad international perspective, he continuously explores and
breaks through frontier technologies in drug innovation. He has successfully
translated a series of anti-cancer drug products, leading his team from laboratory
research to commercialization. He has pioneered several innovative products, including China’s first gene therapy drug (recombinant human endostatin adenovirus
injection) to complete Phase III clinical trials, gene therapy products (recombinant
human interferon adenovirus injection), and China’s first autologous natural killer cell
injection, multi-target oncolytic virus projects, CAR-NK, and stem cell-based
therapies, which have successfully met market demands. His research has been widely
reported by authoritative media such as China Central Television (CCTV), China
Education Television, and Scientific Chinese. In terms of social roles, he has served as a member of the Guangdong Province SARS
Prevention and Treatment Expert Committee, rotating president of the Asia-Pacific
Gene and Cell Therapy Association, vice president of the Guangzhou Overseas
Chinese Students Association, senior member of the American Gene and Cell Therapy
Association, consultant for the Ministry of Science and Technology’s “13th Five-Year” 973 Infectious Disease Program, and honorary professor at The Chinese University of
Hong Kong

Baofa Yu, M.D. Chief Physician in China, Adjunct Professor at University of Texas (El Paso) (2016) and Adjunct Professor at Western University of Health Sciences (2016). He graduated from Peking Union Medical College (Peking Union Medical College) in 1988. He was a post-doctoral fellow at UCSD from 1990 to 1991, Salk from 1992 to 1993, Assistant Adjunct Professor, UCSD from 1994 to 1998. In the United States, he was mainly engaged in the research of cancer drug carrier drug delivery and tumor molecular biology. He invented the new concept of using tumor tissue as a sustained release system of anticancer drugs and the treatment method of sustained release reservoir, which has clinical application value, it is also called ultro-Minimum incision personalized intratumoral chemoimmunotherapy (UMIPIC). In 1998, he returned to China and founded Shandong Baofa Research Institute and Taimei Baofa Cancer Hospital in Dongping rural area with technological investment, and served as the chairman of Shandong Baofa Cancer Treatment Co., LTD., and later established Jinan Baofa Cancer Hospital (2004). Dongping Baofa General Hospital (2011), Beijing Baofa Cancer Hospital (2013) and Immuno Oncology Systems, Inc. This UMIPIC is safe, easy to operate, and reproducible with good benefit for all solid tumor. Today this therapy is accepted to “Clinical Operation Guidelines for Interventional Treatment of Advanced Pancreatic Cancer” (Trial) (7th edition), jointly formulated by the Chinese Anti-Cancer Association, the National Clinical Medical Research Center for Radiology and Therapy, and the National Interventional Medicine Innovation Alliance, Journal of Clinical Radiology, volume 43, number 19, 2024, 1636-1648.

He has published more than 60 papers about this therapy in Nature:Scientific Report, Journal of Cancer, Cancer letter, Cytokin and Growth Factor Reviews, Nature Cancer (under review), J Basic Clin Pharma, J Immunological Sci, Japanese Journal of Gastroenterology and Hepatology, Novel Approaches in Cancer Study,  Academic Journal of Engineering Studies, Nov Res Sci, Journal of Hepatocellular carcinoma, lung Cancer: Target and Therapy, Journal of Liver Research, disorders & therapy, Chinese Journal of Chest,Proc.Natl.Acad.Sci.USA, Pancreas and other journals and many post papers participated in AACR and ASCO meeting.

Our major contribution is that sustained-release therapy integrates the advantages of chemotherapy and immunotherapy, and for the first time, the two have been combined and applied to intratumoral therapy through intervention. It integrates local and global treatment, and increases the concentration and time of drug action through sustained release of drugs within the tumor, which not only plays a local anticancer effect of chemotherapy drugs, but also takes into account the role of systemic immunotherapy, thus making up for the shortcomings of other therapies, providing new ideas and approaches for cancer treatment, especially for middle and advanced tumors, especially for reducing tumor recurrence and inhibiting tumor The transfer has very important value; UMPIC therapy has the advantage of using tumor as antigen source and autologous vaccine, which is also in line with the development trend of Personalized Medicine. And applied to the clinic, hapten combined with chemotherapy drugs for sustained release treatment of pancreatic cancer primary focus, while inducing distal effect, the essence of which is to induce immune response, T-cell-related CD4, CD8, DC, T and NK cells, and B-cell-related tumor autoantibodies: Antibodies to P53, P16, Cmyc, Zeta, IMP1, Koc, Survivin, p62, HCC1 and other oncogenes, this is the first time to find that T and B are involved in the immune response, and the clinical functions of the distal effect and this therapy was selected for “Clinical Operation Guidelines for Interventional Treatment of Advanced Pancreatic Cancer” (Trial) (7th edition) jointly formulated by the Chinese Anti-Cancer Association, the National Clinical Medical Research Center for Radiology and Therapy, and the National Interventional Medicine Innovation Alliance was published at

Journal of Clinical Radiology, volume 43, number 19, 2024, 1636-1648.

Wei-Wei Zhang , MD, PhD was one of the pioneers in Gene Therapy and precision medicine applications. Dr. Zhang also is a corporate executive, with enduring records of technology innovation, strategic partnering, product R&D, commercialization, financing, and business management in biosciences and international transactions.

Dr. Zhang has founded, co-founded, and led operations several biopharma companies (Introgen Therapeutics Inc., Shenzhen SiBiono GeneTech, GenStar Therapeutics, GenWay Biotech, Adventin Inc., and GenBioRx International Corp.) and established two corporate and academic R&D units. With 30+ years of biopharma R&D, business development, and marketing/sales experience, Dr. Zhang played CEO and BOD chairman positions in those companies. Some achievements are highlighted as follows:

1. Invented and developed the World first Gene Therapy Product (Adp53, known as “Gendicine”) for Cancer Therapy (product approved by China SFDA in 2003);
2. Participated in raising the $50M initial funding for Introgen Therapeutics;
3. Founded Shenzhen SiBiono GeneTech Co and raised initial $8 million equivalent RMB;
4. Invented and developed MiniAdFVIII in GenStar Therapeutics, leading the teams from labs to clinical trials, and bringing the company to public on American Stock Exchange (NY), resulted in the corporate value increased 100 times from $6 to $600M; 
5. Developed over 2,600 recombinant proteins and 800 antibodies with 36 ELISA kits;
6. Participated in developing a RMB VC/PE fund in China (total committed $300M).

1995-1998, Dr. Zhang worked as Director of Gene Therapy Unit, Baxter Healthcare, where he participated in $80M operations annual budget, strategic planning, and performance. He led R&D teams to develop gene therapy products and led the international collaboration and partnership of corporate-founded R&D.

Dr. Zhang (77-Class) obtained his M.D. degree in 1982 and M.S. of Toxicology in 1985 from Zhejiang University in China and acquired his PhD of Molecular Biology from Univ. of Alabama in 1989. Dr. Zhang took his junior faculty in gene manipulation and transfer at Baylor College of Medicine in 1989 and Assistant Professor in MD Anderson Cancer Center in 1992. From 1989 to 2007, Dr. Zhang has 16 patents. He has published more than 65 peer-reviewed articles.